Literature DB >> 33415989

Can natural products stop the SARS-CoV-2 virus? A docking and molecular dynamics study of a natural product database.

Jurica Novak1, Hrvoje Rimac1,2, Shivananda Kandagalla1, Maria A Grishina1, Vladimir A Potemkin1.   

Abstract

Background: The SARS-CoV-2 3CLpro is one of the primary targets for designing new and repurposing known drugs. Methodology: A virtual screening of molecules from the Natural Product Atlas was performed, followed by molecular dynamics simulations of the most potent inhibitor bound to two conformations of the protease and into two binding sites.
Conclusion: Eight molecules with appropriate ADMET properties are suggested as potential inhibitors. The greatest benefit of this study is the demonstration that these ligands can bind in the catalytic site but also to the groove between domains II and III, where they interact with a series of residues which have an important role in the dimerization and the maturation process of the enzyme.

Entities:  

Keywords:  3CLpro; COVID-19; SARS-CoV-2; futalosine; molecular dynamics; natural product atlas

Year:  2021        PMID: 33415989      PMCID: PMC7798421          DOI: 10.4155/fmc-2020-0248

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  3 in total

1.  Withasomniferol C, a new potential SARS-CoV-2 main protease inhibitor from the Withania somnifera plant proposed by in silico approaches.

Authors:  Shivananada Kandagalla; Hrvoje Rimac; Krishnamoorthy Gurushankar; Jurica Novak; Maria Grishina; Vladimir Potemkin
Journal:  PeerJ       Date:  2022-06-02       Impact factor: 3.061

2.  A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study.

Authors:  Jurica Novak; Vladimir A Potemkin
Journal:  Mol Divers       Date:  2022-01-10       Impact factor: 3.364

3.  Searching and designing potential inhibitors for SARS-CoV-2 Mpro from natural sources using atomistic and deep-learning calculations.

Authors:  Nguyen Minh Tam; Duc-Hung Pham; Dinh Minh Hiep; Phuong-Thao Tran; Duong Tuan Quang; Son Tung Ngo
Journal:  RSC Adv       Date:  2021-11-29       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.